CooperBiomedical therapeutic div.
Executive Summary
Exploring possibility of licensing to third parties the development, manufacture and sale of its therapeutic division's R&D projects and products as well as the sale of the therapeutic division's remaining operating units. Total fiscal 1984 R&D costs of $2.3 mil. were allocated to: alpha-1 antitrypsin, for the treatment of respiratory diseases; development of a liposome aerosol delivery system; refinement of human cell-produced viral inhibitors; and investigation of an immune system stimulator for use as an anticancer therapeutic.